Atomoxetine Hydrochloride Capsules

The drug selectively inhibits the reuptake of norepinephrine in the brain. The increase in norepinephrine in the prefrontal cortex will help improve a person's attention and memory, and over time it will also cause desensitization of beta-adrenergic receptors. The drug has little effect on serotonin or dopamine receptors.

【Chemical name】(-)-N-methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride 【Molecular formula】C17H21NOHCl 【Molecular weight】291.82

This product is a capsule, and the contents are white to off-white powder.

Atomoxetine hydrochloride is used to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.

Dosage for Children and Adolescents Under 70 kg - Initially, the total daily dose of atomoxetine hydrochloride should be approximately 0.5 mg/kg, and after 3 days of minimum dosing, the dose should be increased to a total daily target dose of approximately 1.2 mg/kg, either as a single dose in the morning or divided equally into two doses in the morning and evening. No additional benefit has been shown for doses above 1.2 mg/kg/day. For children and adolescents, the maximum daily dose should not exceed 1.4 mg/kg or 100 mg, whichever is less. Dosage for Children, Adolescents, and Adults Over 70 kg - Initially, the total daily dose of atomoxetine hydrochloride should be 40 mg, and after 3 days of minimum dosing, the dose should be increased to a total daily target dose of approximately 80 mg, either as a single dose in the morning or divided equally into two doses in the morning and evening. After 2 to 4 weeks of continued use, if the optimal therapeutic effect is still not achieved, the total daily dose can be increased to 100 mg. There is no data to support that the efficacy will be increased at a higher dose. For children and adolescents weighing more than 70 kg and adults, the maximum recommended total daily dose is 100 mg. General medication instructions: Atomoxetine hydrochloride can be taken with or without food; single doses exceeding 120 mg have not been systematically evaluated.

In clinical trials, the most common reasons for patients to withdraw from the study include aggression, irritability, drowsiness and vomiting. The most common adverse reactions include indigestion, nausea, vomiting, fatigue, loss of appetite, dizziness and mood swings. In addition to the adverse reactions seen in children and adolescents, adult patients may also experience dry mouth, erectile dysfunction, impotence, abnormal orgasm, etc.

Patients with closed-angle glaucoma are contraindicated to use this drug because it increases the risk of mydriasis. In addition, this drug should not be used in combination with monoamine oxidase inhibitors (MAOIs); if MAOIs must be given, they should be used at least two weeks after stopping this drug. Patients who are allergic to this drug or other components of the inhibitor are contraindicated to use this drug.

Store at room temperature, which can vary between 15 and 30°C.

10 mg

24 months